Status:
UNKNOWN
Immunotherapy in Upper Tract Urothelial Carcinoma
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18-100 years
Brief Summary
Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized disease is most often radical nephroureterectomy. In advanced/metastatic disease, treatments follow the standa...
Eligibility Criteria
Inclusion
- Age 18 and more
- Diagnosis of urothelial carcinoma (with or without variant histology)
- Advanced/metastatic disease not amenable to local treatment with curative intent
- Treatment with an anti-PD-(L)1 monoclonal antibody initiated between 2016 and 2022
Exclusion
- Patient's opposition to this research
- Urothelial carcinoma of bladder or urethral primary site
- Non-urothelial tumor
- Maintenance immunotherapy initiated without disease progression
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2024
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06113367
Start Date
November 1 2023
End Date
February 28 2024
Last Update
November 2 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.